Log In
BCIQ
Print this Print this
 

CD20 mAb

  Manage Alerts
Collapse Summary General Information
Company Innovent Biologics Inc.
Description mAb targeting protein CD20
Molecular Target CD20
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPreclinical
Standard IndicationHematologic malignancies
Indication DetailsTreat hematologic malignancies
Regulatory Designation
PartnerEli Lilly and Co.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$456.0M

$56.0M

$400.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

03/20/2015

$456.0M

$56.0M

$400.0M

Get a free BioCentury trial today